Bimekizumab Effective for Patients With Moderate to Severe HS
Data from two phase 3 studies "support the use of bimekizumab as a promising new therapeutic option for patients with moderate to severe hidradenitis suppurativa," the authors concluded.
Medscape Medical News
source https://www.medscape.com/viewarticle/phase-3-trials-bimekizumab-effective-moderate-severe-2024a1000alz?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/phase-3-trials-bimekizumab-effective-moderate-severe-2024a1000alz?src=rss
Comments
Post a Comment